Transcription factor E2F1 has been implicated in both apoptosis-promoting and apoptosis-suppressing effects. However, factors that mediate its antiapoptotic effects are still not identified. Using prostate tumor-derived cell lines, we showed here that E2F1 activated the expression of transcription factor EGR1 for promoting cell survival. E2F1 up-regulated the production of EGR1-induced growth factors, epidermal growth factor, platelet-derived growth factor, and insulin-like growth factor II, which in turn activated the phosphoinositide-3-kinase/Akt pathway to resist drug-induced apoptosis. Moreover, E2F1 directly induced the transcription of the Egr1 gene using the KB site located in its proximal promoter. E2F1 physically interacted with the RelA subunit of nuclear factor-KB and modulated its transactivity to fully activate EGR1 transcription. Together, these studies uncovered a novel mechanism for E2F1-induced suppression of apoptosis in prostate cancer.

Immunoglobulins have a pivotal role in disease regulation. Therefore, it is vital to accurately identify immunoglobulins to develop new drugs and research related diseases. Compared with utilizing high-dimension features to identify immunoglobulins, this research aimed to examine a method to classify immunoglobulins and non-immunoglobulins using two features, FC* and GC*. Classification of 228 samples (109 immunoglobulin samples and 119 non-immunoglobulin samples) revealed that the overall accuracy was 80.7% in 10-fold cross-validation using the J48 classifier implemented in Weka software. The FC* feature identified in this study was found in the immunoglobulin subtype domain, which demonstrated that this extracted feature could represent functional and structural properties of immunoglobulins for forecasting.